- Home
- TXO vs MDXG Comparison
TXO vs MDXG Comparison
Compare TXO & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TXO | MDXG |
|---|---|---|
| Founded | 2012 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 781.2M | 672.8M |
| IPO Year | 2022 | 2007 |
Fundamental Metrics
Financial Performance| Metric | TXO | MDXG |
|---|---|---|
| Price | $13.88 | $3.32 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $19.75 | $7.00 |
| AVG Volume (30 Days) | 125.8K | ★ 1.8M |
| Earning Date | 11-03-2026 | 10-28-2026 |
| Dividend Yield | ★ 12.27% | N/A |
| EPS Growth | N/A | ★ 14.29 |
| EPS | N/A | ★ N/A |
| Revenue | $401,012,000.00 | ★ $418,630,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $23.63 | $12.42 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 41.80 | 19.99 |
| 52 Week Low | $10.12 | $3.03 |
| 52 Week High | $15.58 | $7.51 |
Technical Indicators
Market Signals| Indicator | TXO | MDXG |
|---|---|---|
| Relative Strength Index (RSI) | 48.29 | 28.04 |
| Support Level | $13.58 | $3.11 |
| Resistance Level | $14.01 | $3.84 |
| Average True Range (ATR) | 0.55 | 0.21 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 51.13 | 25.91 |
Price Performance
Historical ComparisonAbout TXO TXO Partners L.P.
TXO Partners LP is focused on the acquisition, development, optimization, and exploitation of oil, natural gas, and natural gas liquid reserves in North America. Its operations focus on enhancing the development and operation of producing properties through its concentration on efficiency and optimizing exploitation of current wells.
About MDXG MiMedx Group Inc
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, the company sells allografts for ophthalmic surgery and dental applications through licenses to third parties.